Why PTC Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
PTC jumped 34.7% after Schneider Electric offered $22.6B; Columbus Acquisition soared 657.5%, while Zeta Network Group fell 23.3% premarket.
Stocks · News reference
SRX Global’s Portfolio Company Smartkem To Merge With Ferrox Critical Minerals, Strengthening Its Critical Minerals Sourcing
SRX Global Inc. (NYSE:SRXH) (the "Company", or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — SmartKem, Inc. (SMTK)
Filed: 2026-09-21 AccNo: 0001104659-26-109357 Size: 190 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
SmartKem shares are trading lower after the company announced a preliminary prospectus for the resale of up to 15.1 million shares by selling stockholders. The company registered up to a 30 million shares under $500 million Keystone Equity financing agreement.
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
SRX Global Inc. announced a definitive agreement to acquire CERo Therapeutics Holdings, Inc., an innovative cellular immunotherapy company developing CER-1236 for hematologic malignancies. The acquisition will be structured through a wholly-owned SPV (CERO 1236) to avoid diluting existing SRX shareholders. The transaction is expected to accelerate CER-1236's clinical development and provide CERo with enhanced access to capital and operational resources. CERo has treated six patients in its Phase 1 CERTAIN-T trial with no dose-limiting toxicities observed at increased dose levels.
SRX Global Inks Stock Purchase Agreement With Cero Therapeutics; To Acquire All Outstanding Stock Of Cero Therapeutics
https://www.sec.gov/ix?doc=/Archives/edgar/data/1471727/000149315226046085/form8-k.htm